| Literature DB >> 34597277 |
Yipeng Zhu1, Wenwei Qian1, Liangyu Huang2, Yihan Xu3, Zhen Guo2, Lei Cao2, Jianfeng Gong2, J Calvin Coffey4, Bo Shen5, Yi Li1,2, Weiming Zhu1,2.
Abstract
INTRODUCTION: The mesentery is involved in Crohn's disease. The impact of the extent of mesenteric resection on postoperative disease progression in Crohn's disease remains unconfirmed. This study aimed to determine the association between resection of the mesentery and postoperative outcomes in patients with Crohn's colitis (CC) undergoing colorectal surgery.Entities:
Mesh:
Year: 2021 PMID: 34597277 PMCID: PMC8483874 DOI: 10.14309/ctg.0000000000000407
Source DB: PubMed Journal: Clin Transl Gastroenterol ISSN: 2155-384X Impact factor: 4.488
Demographic data and disease characteristics of patients
| Group LME (n = 60) | Group EME (n = 66) | ||
| Male sex, n (%) | 47 (78.3) | 42 (63.6) | 0.07 |
| Age of onset, mean ± SD, yr | 26.85 ± 10.82 | 25.23 ± 9.71 | 0.38 |
| Age at the index surgery, mean ± SD, yr | 31.15 ± 10.36 | 30.42 ± 10.15 | 0.69 |
| Duration of disease, mean ± SD, mo | 51.19 ± 49.36 | 61.61 ± 52.19 | 0.25 |
| BMI, mean ± SD, kg/m2 | 18.48 ± 3.19 | 18.04 ± 2.49 | 0.48 |
| Surgery history, n (%) | 6 (10.0) | 1 (1.5) | 0.09 |
| Smoking history, n (%) | 9 (15.0) | 5 (7.6) | 0.19 |
| Preoperative medication, n (%) | 32 (53.3) | 38 (57.6) | 0.63 |
| Immunosuppressants | 19 (31.7) | 23 (34.8) | 0.71 |
| Infliximab | 4 (7.1) | 4 (6.3) | 1.00 |
| Corticosteroids | 21 (35.0) | 25 (37.9) | 0.74 |
| Age at diagnosis, n (%), yr | 0.51 | ||
| A1 ≤16 | 7 (11.7) | 4 (6.1) | 0.27 |
| A2 17-40 | 44 (73.3) | 50 (75.8) | 0.76 |
| A3 > 40 | 12 (15.0) | 12 (18.2) | 0.80 |
| Disease location, n (%) | 0.32 | ||
| L2 (colonic) | 32 (53.3) | 41 (62.1) | 0.32 |
| L3 (ileocolonic) | 28 (46.7) | 25 (37.9) | 0.32 |
| L4 (upper tract) | 1 (1.7) | 4 (6.1) | 0.42 |
| Disease behavior, n (%) |
| ||
| B1 | 0 (0) | 3 (4.5) | 0.28 |
| B2 | 20 (33.3) | 39 (59.1) |
|
| B3 | 40 (66.7) | 24 (36.4) |
|
| P | 25 (41.7) | 22 (33.3) | 0.33 |
| ASA score, n (%) | 0.47 | ||
| ≥3 | 10 (16.7) | 8 (12.1) | |
| <3 | 50 (83.3) | 58 (87.9) | |
| Preoperative CRP, mean ± SD, mg/L | 16.10 ± 27.77 | 12.60 ± 23.12 | 0.30 |
| Preoperative albumin, mean ± SD, g/L | 37.11 ± 4.99 | 37.28 ± 5.91 | 0.50 |
| Postoperative medicine prophylaxis, n (%) | 30 (50.0) | 40 (60.6) | 0.23 |
| Immunosuppressants | 29 (48.3) | 38 (57.6) | 0.30 |
| Biologics | 2 (3.3) | 4 (6.1) | 0.77 |
| No immunosuppressants or biologics, n (%) | 30 (50.0) | 26 (39.4) | 0.23 |
| Site of colorectal surgery, n (%) | 0.22 | ||
| Right hemicolectomy | 26 (43.3) | 32 (48.5) | 0.56 |
| Transverse colectomy | 4 (6.7) | 3 (4.5) | 0.90 |
| Left hemicolectomy | 21 (35.0) | 14 (21.2) | 0.08 |
| Proctectomy | 2 (3.3) | 1 (1.5) | 0.93 |
| Total colectomy | 7 (11.7) | 16 (24.2) | 0.07 |
| Stoma creation, n (%) | 14 (23.3) | 11 (16.7) | 0.35 |
| Terminal ileum | 8 (57.1) | 9 (81.8) | 0.38 |
| Ascending colon | 0 (0) | 1 (9.1) | 0.44 |
| Transverse colon | 3 (21.4) | 0 (0) | 0.31 |
| Descending colon | 3 (21.4) | 1 (9.1) | 0.78 |
| Microscopic resection margin positive, n (%) | |||
| Proximal margin | 4 (8.7) | 4 (7.3) | 1.00 |
| Distal margin | 3 (6.5) | 4 (7.3) | 1.00 |
| Stoma margin | 1 (7.1) | 1 (9.1) | 1.00 |
ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in m2); CRP, C-reactive protein; EME, extensive mesenteric excision; LME, limited mesenteric excision.
Postoperative short-term outcomes
| Group LME (n = 60) | Group EME (n = 66) | ||
| Blood loss, mean ± SD, mL | 132.25 ± 85.53 | 83.10 ± 56.19 |
|
| Length of hospital stay, mean ± SD, d | 12.64 ± 8.57 | 10.49 ± 5.17 | 0.47 |
| Blood transfusion, n (%) | 4 (6.7) | 6 (9.1) | 0.86 |
| Time to return to bowel movements, mean ± SD, d | 8.70 ± 3.71 | 9.13 ± 3.93 | 0.58 |
| Readmission, n (%) | 2 (3.3) | 2 (3.0) | 1.00 |
| Reoperation, n (%) | 3 (5.0) | 2 (3.0) | 0.91 |
| Postoperative morbidity, n (%) | 14 (23.3) | 17 (25.8) | 0.75 |
| Postoperative complications, n (%) | |||
| Wound infection | 4 (28.6) | 3 (17.6) | 0.67 |
| Intra-abdominal abscess | 0 (0) | 2 (11.8) | 0.49 |
| Anastomotic leak | 5 (35.7) | 2 (11.8) | 0.20 |
| Ileus | 0 (0) | 2 (11.8) | 0.49 |
| Intra-abdominal bleeding | 2 (14.3) | 0 (0) | 0.20 |
| Dysfunction of gastrointestinal recovery | 2 (14.3) | 6 (35.3) | 0.24 |
| Other | 1 (7.1) | 2 (11.8) | 1.00 |
EME, extensive mesenteric excision; LEM, limited mesenteric excision.
Figure 1.(a) Surgical recurrence in group LME and group EME. (b) Kaplan-Meier estimates demonstrating the cumulative incidence of surgical recurrence in group LME and group EME. EME, extensive mesenteric excision; LME, limited mesenteric excision. *P< 0.05.
Univariate and multivariate analysis of risk factors for surgical recurrence
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | HR (95% CI) | |||
| Male sex | 0.49 (0.17–1.42) | 0.19 | ||
| Duration of disease | 0.10 (0.99–1.01) | 0.69 | ||
| Age at the index surgery | 1.01 (0.97–1.05) | 0.56 | ||
| Surgery history | 0.94 (0.13–6.92) | 0.95 | ||
| Age at diagnosis | 1.02 (0.98–1.05) | 0.44 | ||
| Site of resection | — | 0.55 | ||
| Penetrating vs stricturing phenotype | 1.47 (0.64–3.35) | 0.36 | 1.47 (0.61–3.54) | 0.40 |
| Perianal disease | 1.02 (0.46–2.26) | 0.97 | ||
| Smoking history (yes vs no) | 0.001* | 0.002 | ||
| Postoperative biologics vs immunosuppressants | 0.04 (0.00–154.61) | 0.45 | ||
| Postoperative biologics vs none | 0.04 (0.00–74.64) | 0.40 | ||
| Postoperative immunosuppressants vs none | 0.75 (0.33–1.72) | 0.50 | ||
| LME vs EME | 0.02* | 0.04* | ||
| Stoma vs primary anastomosis | 0.65 (0.24–1.74) | 0.39 | ||
CI, confidence interval; EME, extensive mesenteric excision; HR, hazard ratio; LME, limited mesenteric excision.
P< 0.05.
Figure 2.(a) Surgical recurrence in subgroup anastomosis. (b) Kaplan-Meier estimates demonstrating the cumulative incidence of surgical recurrence in group LME and group EME for subgroup anastomosis. EME, extensive mesenteric excision; LME, limited mesenteric excision. *P< 0.05.
Univariate and multivariate analysis of patients with anastomosis
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | HR (95% CI) | |||
| Male sex | 1.73 (0.71–4.23) | 0.23 | ||
| Duration of disease | 0.99 (0.98–1.00) | 0.11 | ||
| Age at the index surgery | 1.01 (0.97–1.05) | 0.60 | ||
| Surgery history | 0.05 (0.00–256.57) | 0.49 | ||
| Age at diagnosis | 1.02 (0.99–1.06) | 0.21 | ||
| Site of resection | — | 0.38 | ||
| Penetrating vs stricturing phenotype | 1.89 (0.86–4.16) | 0.11 | 1.22 (0.47–3.20) | 0.68 |
| Perianal disease | 0.91 (0.43–1.96) | 0.82 | ||
| Smoking history (yes vs no) |
| |||
| Postoperative biologics vs immunosuppressants | 0.04 (0.00–116.84) | 0.44 | ||
| Postoperative biologics vs none | 0.04 (0.00–57.02) | 0.38 | ||
| Postoperative immunosuppressants vs none | 0.83 (0.39–1.77) | 0.63 | ||
| LME vs EME | ||||
CI, confidence interval; EME, extensive mesenteric excision; HR, hazard ratio; LME, limited mesenteric excision.
P< 0.05.